LAVA Therapeutics, supported by Ysios Capital, Announces Pricing of Initial Public Offering

by Ysios Capital

LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of i...

Read more

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Read more

Splice Bio, backed by Ysios Capital, Asabys Partners and Caixa Capital Risc, appoints Jean-Philippe Combal as Chairman of the Board of Directors

by Ysios Capital

Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...

Read more

CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor

by Ysios Capital

CorWave raises 35 million euros to fund the next stages of its development, with the ambition to become a world-class medtech company serving heart failure patients. The capital increase is subscribed...

Read more

Ysios Capital portfolio company Galecto, Inc. prices IPO on Nasdaq

by Ysios Capital

Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company Galecto Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq G...

Read more

Galecto Announces Pricing of Initial Public Offering

by Ysios Capital

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad r...

Read more

SparingVision Raises €44.5 Million in a round led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital

by Ysios Capital

SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...

Read more

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

by Ysios Capital

Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials

Read more

Minoryx Therapeutics, participated by Ysios and Caixa Capital Risc, and Sperogenix Therapeutics enter into an exclusive license agreement

by Ysios Capital

Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...

Read more

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

by Ysios Capital

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...

Read more

ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio

by Ysios Capital

Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partner...

Read more

VarmX raises €32 million in Series B round led by Ysios Capital and INKEF Capital

by Ysios Capital

The oversubscribed round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate. Founding investor, BioGeneration Ventures (BGV) and the regional economic ...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Voice analysis with artificial intellige...

by Hospital Universitari de Bellvitge

A study by the International Center for Numerical Methods in Engineeri...

Photos Stream